

# 18th International Myeloma Workshop

**SEPTEMBER 8-11, VIENNA AUSTRIA** 

# PRELIMINARY PROGRAM



#### Wednesday, September 8th

09:00-10:00	OPENING SESSION			
	Welcome to IMW18	Organizers of IMW18		
	Historical perspectives: Milestones in Myeloma	Robert Kyle		
	IMS President Address	Nikhil Munshi		
PLENARY SE	SSIONS			
10:00-11:15	Precursor Conditions			
	Session Chairs: Mario Boccadoro/Sigurdur Kristinson			
	Genomic evolution - germinal B cell to MGUS/SMM/MM	Brian Walker		
	Role of the immune Microenvironment in the journey to MGUS/SMM/MM	Madhav Dhodapkar		
	Molecular Timing of Initiation	Niels Weinhold		
	Risk factors for MGUS/SMM progression	Vincent Rajkumar		
	Management of Smoldering Myeloma	Marivi Mateos		
	Should we screen for precursor conditions?	Irene Ghobrial		
11:15-12:30	Molecular dissection of myeloma			
	Session Chairs: Andrew Spencer/Roger Owen			
	Clonal diversity in Myeloma	Mehmet Samur		
	Transcriptome	Jill Corre		
	Epigenomic	Wee Joo Chng		
	Microbiome	Leif Bergsagel		
	Proteomics	Arun Wiita		
	Metabolomics	Rafael Fonseca		
12:30-13:30	LUNCH			
13:30-14:30	MULTIPLE MYELOMA DIAGNOSIS			
	Session Chairs: Sonja Zweegman/P. Joy Ho			
	Diagnostic criteria and work-up in 2021	Shaji Kumar		
	How should we define standard and high risk MM in 2022?	Herve Avet-Loiseau		
	Role of imaging in diagnosis and response assessment	Elena Zamagni		
	Circulating tumor cells and tumor DNA for response assessment	Bruno Paiva		
	Mass-spec to monitor the treatment response	Dave Murray		
	Assessment of patient frailty and functional status	Alessandra Larocca		
14:30-15:15	IMS AWARDS			
-	Bart Barlogie/Ken Anderson Young Investigator Award Pre	sentation		
	Waldenstrom Award Presentation and Lecture			

17:45-19:15	WELCOME RECEPTION		
	I square effort updates and future directions	Brian Durie	
	Panelists: TBC		
	Session Moderators: Nikhil Munshi/Jesús San Miguel		
	In 2021, what is the unmet need in Myeloma?		
16:45-17:45	HOT TOPICS IN MYELOMA		
15:45-16:45	INDUSTRY SUPPORTED SYMPOSIUM		
15.45 16.45	INDUSTRY CHRRORTER CYMROSIUM		
15:15-15:45	BREAK		

### Thursday, September 9th

09:00-09:30	OPENING SESSION	
08:00-09:00	CAREER DEVELOPMENT WORKSHOP Writing successful grants	Suzanne Lentzsch/ Diane Jelinek
00.00 00.00	CAREER REVELORMENT WORKSHOP	•
	Allogeneic Stem Cell Transplantion in MM	Amrita Krishnan/ Charlotte Pawlyn
	Management of POEMS	Angela Dispenzieri/ Anita D'Souza
	Management of Waldeström's Macroglobulinemia	Ramón García Sanz/ Prashant Kapoor
	Management of LC Amyloidosis	Vaishali Sanchorawala/ Eli Muchtar
	Special forms of MM: macrofocal, non-secretory MM	Stathis Kastritis/ Jacob Laubach
	Management of Monoclonal gammopathy of clinical significance	Laura Rosiñol/ Ajay Nooka
	Management of Monoclonal gammopathy of renal significance	Javier de la Rubia/ Moshe Gatt
	Plasma cell leukemia	Artur Jurczyszyn/Ravi Vij
	Extramedullary disease	Cyrille Touzeau/TBC
08:00-09:00	MEET THE EXPERTS	

09:30-10:30	PLENARY SESSIONS			
	Newly diagnosed Multiple Myeloma: Curre	Newly diagnosed Multiple Myeloma: Current Treatment Approaches		
	Session Chairs: Martha Lacy/David Seigel			
	Treatment of Newly Diagnosed Myeloma Tra Eligible: what is the optimal induction?	insplant Philippe Moreau		
	ASCT in NDMM transplant eligible	Michele Cavo		
	Consolidation Strategies for MM	Pieter Sonneveld		
	Maintenance Strategies for MM	Hartmut Goldschmidt		
	Treatment of Newly Diagnosed Myeloma Non-Transplant Eligible	Theirry Facon		
10:30-11:45	ORAL ABSTRACT SESSION			
	Session Chairs: Lugui Qui/Ed Stadtmauer	Session Chairs: Paola Neri/Dharminder Chauhan/Niklas Zojer		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
PLENARY S	FSSIONS			
11:45-12:45	Management of relapsed/refractory MM patients			
	Session Chairs: Meral Beksac / Bob Orlowski			
	Approach to first relapse	Meletios-Athanassios Dimopoulos		
	Management of triple refractory patients	Sagar Lonial		
	Role of immunotherapies for relapsed MM, when and which?	Saad Usmani		
	Personalized treatment of relapsed MM: gen			
12:45-13:45	EXPOSITIONS AND BREAK			
13:45-15:15	INDUSTRY SUPPORTED SYMPOSIUM			
15:15-16:30	ORAL ABSTRACT SESSION			
	Session Chairs: Natalie Callander/Merav Leiba	Session Chairs: Enrique Ocio/Annemeik Brojil		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		

16:30-17:00	EXPOSITIONS AND BREAK	
17:00-18:00	INDUSTRY SUPPORTED SYMPOSIUM	
18:00-19:00	POSTER SESSION	
19:30-22:30	FACILITY DINNER	

## Friday, September 10th

08:00-09:00	MEET THE EXPERTS			
	Covid-19 and MM	Wenming Chen/ Sarah Holstein		
	Vaccination and prophylaxis in Myeloma			
	Management of cellular therapy-related t	oxicities Jesus Berdeja/Kr		
	Bone disease control in Myeloma			
	Management of MM patients with renal in			
	Which is the ideal patient to be refered for vs bi-specific vs ADC?	CAR-T Melissa Alsina/ N		
	Racial disparity and monoclonal gammop	athies Sikander Ailawac Craig Cole	hi/	
08:00-09:00	CAREER DEVELOPMENT WORKSHOP			
	Developing your first clinical trial	Simon Harrison/ Jean-Luc Harrous	eu	
09:00-09:30	OPENING SESSION			
	Future of myeloma treatment	Jesus San Miguel		
09:30-10:30	IMS/EHA SYMPOSIUM			
	Immune Therapies: A game changer for Hematological Malignancies Chairs: TBC			
	CART	TBC		
	Other Immune Approaches	TBC		
10:30-11:45	ORAL ABSTRACT SESSION			
	Session Chairs: Graham Jackson/TBC	Session Chairs: Ruth De Tute/Aurore Perrot/Tomas Jeline		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abst</li> </ul>	racts	
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abst</li> </ul>	racts	
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abst</li> </ul>	racts	
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abst</li> </ul>	racts	
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abst</li> </ul>	racts	

#### PLENARY SESSIONS

rrent strategies for AL patients nat are the novel approaches in WM? noclonal gammopathy of clinical significant proclonal gammopathy of renal significant CPOSITIONS, POSTER SESSION CRAL ABSTRACT SESSION Ession Chairs:	Giovanni Palladini Steve Treon ficance Joan Blade nnce Nelson Leung  ON AND LUNCH  OSIUM	
nat are the novel approaches in WM? conoclonal gammopathy of clinical significant conclonal gammopathy of renal significant conclonal gammopathy of clinical significant conclonal gammopathy of clinical significant conclonal gammopathy of renal significant conclonal gammopathy conclonal gammopathy of renal significant conclonal gammopathy of renal significant conclonal gammopathy conclonal gammopathy of renal significant conclonal gammopathy conclonal gammopathy conclonal gammopathy conclonal gammopathy conclonal gammopathy concl	Steve Treon ficance Joan Blade ince Nelson Leung ON AND LUNCH OSIUM	
onoclonal gammopathy of clinical signification clonal gammopathy of renal signification control sympositions. Poster session chairs:	ficance Joan Blade Ince Nelson Leung  ON AND LUNCH  OSIUM	
onclonal gammopathy of renal significant of the second significant of the second secon	ON AND LUNCH OSIUM	
CPOSITIONS, POSTER SESSION  CRAL ABSTRACT SESSION  Ssion Chairs:	ON AND LUNCH OSIUM	
DUSTRY SUPPORTED SYMPORAL ABSTRACT SESSION assion Chairs:	O S I U M	
RAL ABSTRACT SESSION assion Chairs:		
ssion Chairs:		
	6 : 61 :	
	Session Chairs:	
s Hillengass/Angelo Maiolino	Constantine Mitsiades/Virgina Abello	
elected from Submitted Abstracts	<ul> <li>Selected from Submitted Abstracts</li> </ul>	
elected from Submitted Abstracts	<ul> <li>Selected from Submitted Abstracts</li> </ul>	
elected from Submitted Abstracts	<ul> <li>Selected from Submitted Abstracts</li> </ul>	
elected from Submitted Abstracts	<ul> <li>Selected from Submitted Abstracts</li> </ul>	
elected from Submitted Abstracts	Selected from Submitted Abstracts	
REAK		
INDUSTRY SUPPORTED SYMPOSIUM		
OT TOPICS IN MYELOMA		
Covid-19 in MM: what we have learnt?		
Session Moderators: Karthik Ramasamy/Douglas Joshua		
nat have we leaned?	TBC	
nelists	Joaquín Martinez, Pan Malhotra, Heinz Ludw Juan Du, Dorotea Fant Jakub Radocha	
	OT TOPICS IN MYELOMA  ovid-19 in MM: what we have learnt	

### Saturday, September 11, 2021

08:00-09:00	MEET THE EXPERTS			
	Animal models for myeloma		Karin Vanderkerkin/ Marta Chesi	
	Genomic techniques		Mark Bustoros/ Ruben Carrasco	
	Approaches to proteomic analysis		Saloman Manier/Naomi Puig	
	Primary sample processing and enrichme	Primary sample processing and enrichment techniques		
	Single cell approaches		Manoj Bhasin/Jens Lohr	
	Assessing the immune system		Hearn Cho/Tax Kourelis	
	Metabolomics techniques in MM		Malathy Shanmugam/ Wilson Gonsalves	
	ChIP in Myeloma		Adam Sperling/TBC	
08:00-09:00	CAREER DEVELOPMENT WORK	SHOP		
	Setting up your laboratory research program		Rodger Tiedeman/ Larry Boise	
10:00-11:15	ORAL ABSTRACT SESSION			
	Session Chairs: Jae Hoon Lee/Elizabet Manasanach	Session Chairs: Mariateresa Fulciniti/Nicolo Bolli/ Maria-Theresa Krauth		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstracts</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	<ul> <li>Selected from Submitted Abstra</li> </ul>		
	<ul> <li>Selected from Submitted Abstracts</li> </ul>	• Selected from Submitted Abstracts		
PLENARY S	ESSIONS			
11:15-13:15	Great Debates in Myeloma			
	Moderators: Ludwig/Goldschmidt/Einsele/Ho	ajek		
	Transplant for every NDMM transplant eli	Transplant for every NDMM transplant eligible?		
	MRD-guided therapy?		Sundar Jagannath/ Ola Landgren	
	Stratification based on genomics ready for primetime?		Gareth Morgan/ Faith Davies	
	Which is the best immune approach to replace ASCT? CAR-T vs Bispecific antibodies		Hermann Einsele/ Hari Parameswaran	
	Can we give our patient treatment free in	Can we give our patient treatment free intervals?		
	The role of alkylator in MM		Donna Reece/ Jeff Wolf	

PLENARY SI	ESSIONS			
13:45-14:45	Supportive care management			
	Session Chairs: Andrezj Jakubowiak/Rafat Abonour			
	Management of renal failure	Jean-Paul Fermand		
	Approaches to bone health	Evangelos Terpos		
	Management of infections	Michel Delforge		
	Toxicity management	TBC		
	Vaccinations in myeloma including covid-19	Heinz Ludwig		
14:45-15:45	Immune Therapies			
	Session Chairs: Qing Yi/Ivan Borello			
	Mechanism of resistance to CAR-T cells and bispecifics	Yi Lin		
	How to improve the efficacy of CAR-T cells and bi-specifics?	Michael Hudecek		
	Allo-CAR-T cels	Roman Hajek		
	CAR- NK cells	Adam Cohen		
	Vaccination Therapies for Myeloma	David Avigan		
15:45-16:45	Clinical Trials in Progress			
	Moderators: William Bensinger/Raymond Comenzo			
	North America	Jonathan Kaufman		
	Europe	Xavier Leleu		
	South America	Vania Hungria		
	Asia	Jeffrey Huang		
	Australia	Hang Quach		
16:45-16:55	WELCOME TO IMW19			
	Organizers of IMW19			
16:55-17:00	CLOSING COMMENTS			
	Organizers of IMW18	Ludwig/Goldschmidt/ Einsele/Hajek		

#### The IMS gratefully acknowledges the following organizations for their sponsorship of the 18th International Myeloma Workshop:

TITANIUM LEVEL





PLATINUM LEVEL







SILVER LEVEL

